|1.||Charpentier, Eric: 2 articles (11/2015 - 12/2014)|
|2.||Garcia-Ribas, Ignacio: 2 articles (11/2015 - 12/2014)|
|3.||Carlson, Robert W: 2 articles (06/2015 - 12/2014)|
|4.||O'Shaughnessy, Joyce: 2 articles (12/2014 - 01/2011)|
|5.||Winer, Eric P: 2 articles (12/2014 - 08/2014)|
|6.||de Bono, Johann S: 2 articles (12/2013 - 12/2011)|
|7.||Bradley, Charles: 2 articles (04/2011 - 01/2011)|
|8.||Kirsten, Eva: 2 articles (09/2009 - 02/2002)|
|9.||Hakam, Alaeddin: 2 articles (09/2009 - 02/2002)|
|10.||Kun, Ernest: 2 articles (09/2009 - 02/2002)|
|1.||Breast Neoplasms (Breast Cancer)
12/01/2013 - "Iniparib was purported to be a PARP inhibitor that showed promising results in randomized phase II trials in patients with triple-negative breast cancer. "
12/07/2011 - "Such an outcome may explain the recently reported trial results for iniparib in triple-negative breast cancer. "
06/01/2013 - "In this investigation, we compared the antiproliferative activity of two PARP/putative PARP inhibitors, i.e., olaparib and iniparib, in a panel of 14 breast cancer cell lines (seven tripe-negative and seven non-triple-negative). "
06/01/2013 - "Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines."
01/01/2013 - "Wild-type BRCA1/2 breast cancer cells (i.e., MCF-7 and ZR-75-1 lines) were genetically manipulated to downregulate ATM expression then assayed for cytostaticity/cytotoxicity upon treatment with PARP inhibitors, olaparib and iniparib. "
03/01/2013 - "Iniparib shows promise in early clinical trials; however, understanding the pathways of cytotoxicity will be crucial as cancer therapy becomes increasingly individualized."
04/24/2012 - "Only Olaparib and Iniparib, which are in clinical cancer therapy trials, as well as 4-AN inhibited SSB repair. "
09/01/2010 - "These trials will clarify the role of iniparib in the treatment of cancer, including TNBC."
03/01/2013 - "Although iniparib is only active in cancer cells, the exact mechanism of action remains unclear. "
01/15/2012 - "Furthermore, both iniparib and its nitroso metabolite form protein adducts nonspecifically in tumor cells. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
03/01/2013 - "The authors identified the mechanistic and clinical data available on the role of iniparib in ovarian cancer. "
03/01/2013 - "A review of iniparib in ovarian cancer."
01/01/2012 - "After promising results of phase I and II trials with most commonly investigated PARP inhibitors--iniparib and olaparib--which recruited patients with triple negative breast cancer and ovarian cancer, further studies started. "
03/01/2013 - "Preliminary data from Phase II studies of iniparib for the treatment of platinum-sensitive and platinum-resistant recurrent ovarian cancer show improvement in survival compared to historic controls. "
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
04/01/2011 - "Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer."
04/01/2011 - "This report describes the case of a patient with a germline BRCA2 mutation and an associated pancreatic cancer treated with iniparib (BSI-201), a PARP inhibitor, who demonstrated a complete pathologic response to this agent. "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/01/2014 - "This randomized phase II study investigated the addition of iniparib to gemcitabine-cisplatin in metastatic non-small-cell lung cancer (NSCLC) patients. "
11/01/2014 - "A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer."
01/01/2014 - "Various novel compounds and chemotherapeutics were introduced in 2013 patents such as taxane, quinazoline, arylamino purine, benzodiazepine, pyrrolopyrimidine, nitrobenzamide, cyclopropane amide, 4-iodo-3-nitrobenzamide, heteroaryl (alkyl) dithiocarbamate, and histone deacetylase in treating non-small-cell lung cancer and piperidine, piperazine, picoplatin, and arsenic trioxide in treating small-cell lung cancer. "
|4.||Reactive Oxygen Species (Oxygen Radicals)
|6.||Type I DNA Topoisomerases (Topoisomerase I)
|9.||2- ((R)- 2- methylpyrrolidin- 2- yl)- 1H- benzimidazole- 4- carboxamide
|1.||Drug Therapy (Chemotherapy)